JC
HZNP

JB Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

JB Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,263
Closed -$978K – 239
2022
Q2 		$978K Buy
12,263
+568
+5% +$53.8K 0.1% 101
2022
Q1 		$1.23M Buy
11,695
+858
+8% +$83.6K 0.12% 81
2021
Q4 		$1.17M Buy
10,837
+1,520
+16% +$166K 0.11% 90
2021
Q3 		$1.02M Buy
+9,317
New +$967K 0.13% 98

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

JB Capital's HZNP Position: Q3 2022 in Review

JB Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 12,263 shares — an estimated $978K sold.

JB Capital first reported a position in HZNP in Q3 2021 and held it in 4 quarters. The position peaked at $1.23M in Q1 2022. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

  • JB Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • JB Capital sold 12,263 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $978K.
  • JB Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 4 quarters.
  • JB Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.23M in Q1 2022.
  • 530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on JB Capital's 13F filing for Q3 2022, filed 14 Oct 2022.